European Biotech Acquisition Corp. was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on identifying promising opportunities in the life sciences industry in Europe. The members of the management team are associated with LSP, one of Europe’s largest and most experienced healthcare investment firms.
Company profile
Ticker
OCS, OCS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
OCS stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Mar 23
25-NSE/A
Exchange delisting (amended)
2 Mar 23
8-K
Departure of Directors or Certain Officers
28 Feb 23
10-K
2022 FY
Annual report
27 Feb 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
21 Feb 23
DEFA14A
Additional proxy soliciting materials
14 Feb 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
13 Feb 23
DEFM14A
Proxy related to merger
3 Feb 23
UPLOAD
Letter from SEC
31 Jan 23
425
Business combination disclosure
30 Jan 23
Latest ownership filings
SC 13G
GLAZER CAPITAL, LLC
14 Feb 23
SC 13G
PERISCOPE CAPITAL INC.
13 Feb 23
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
6 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 22
SC 13G
LSP Sponsor EBAC B.V.
8 Feb 22
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
27 Jan 22
3
Mohammad Sohail Fazeli
14 May 21
SC 13G
CITADEL ADVISORS LLC
2 Apr 21
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
24 Mar 21
3
de Stolpe Onno van
15 Mar 21
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 308.49 k | 308.49 k | 308.49 k | 308.49 k | 308.49 k | 308.49 k |
Cash burn (monthly) | (no burn) | 46.65 k | 389.01 k | 234.83 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | 726.87 k | 6.06 mm | 3.66 mm | n/a | n/a |
Cash remaining | n/a | -418.38 k | -5.75 mm | -3.35 mm | n/a | n/a |
Runway (months of cash) | n/a | -9.0 | -14.8 | -14.3 | n/a | n/a |
Institutional ownership, Q1 2023
12.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 34 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 4.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sponsor EBAC B.V. LSP | 3.59 mm | $0.00 |
Integrated Core Strategies | 793.02 k | $0.00 |
News
Chardan Capital Maintains Buy on Oculis Holding, Maintains $30 Price Target
19 Mar 24
Baird Maintains Outperform on Oculis Holding, Lowers Price Target to $35
19 Mar 24
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $29 Price Target
29 Feb 24
Oculis Updates On Late-Stage Clinical Trials At R&D Day
28 Feb 24
Press releases
Oculis to Participate at Upcoming April Investor Conferences
4 Apr 24
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
18 Mar 24
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
28 Feb 24
Oculis to Present at Upcoming February Investor Conferences
29 Jan 24
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
22 Jan 24